Compounds and compositions for treating conditions associated with NLRP activity

US11203579B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Luigi Franchi · Ann Arbor, US
• Shomir Ghosh · Brookline, US
• Gary D. Glick · Ann Arbor, US
• Jason Katz · Leominster, US
• Anthony Opipari · Dexter, US
• William R. Roush · West Jupiter, US
• Hans Martin Seidel · Concord, US
• Dong-Ming Shen · Edison, US
• Shankar Venkatraman · Lansdale, US
• David G. Winkler · Arlington, US

Key dates

• Filing date: Jul 23, 2018
• Grant date: Dec 21, 2021
• Expiry date: Jul 23, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, System…